You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, B-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Relmacabtagene Autoleucel Injection
  • (no location specified)
Apr 13, 2023

Lymphoma, B-Cell Trial in San Antonio (R-Chop and Roflumilast)

Not yet recruiting
  • Lymphoma, B-Cell
  • R-Chop and Roflumilast
  • San Antonio, Texas
    Mays Cancer Center, UT Health San Antonio
Mar 31, 2023

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023